<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2023 7:54:25 PM-->
<!--Modified on: 3/31/2023 7:54:25 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://nrxpharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://nrxpharma.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://nrxpharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#DisclosureReverseRecapitalizationEffectOnCashFlowsAndEquityDetails" roleURI="http://nrxpharma.com/role/DisclosureReverseRecapitalizationEffectOnCashFlowsAndEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://nrxpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#DisclosureAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://nrxpharma.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#DisclosureFairValueMeasurementsConvertibleNotePayableDetails" roleURI="http://nrxpharma.com/role/DisclosureFairValueMeasurementsConvertibleNotePayableDetails" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalIncomeTaxRateDetails" roleURI="http://nrxpharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalIncomeTaxRateDetails" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" roleURI="http://nrxpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="nrxp-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://nrxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <calculationLink xlink:role="http://nrxpharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638158892603846509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638158892603846509" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158892603846509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638158892603846509" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158892603846509" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638158892603858426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638158892603846509" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638158892603858426" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638158892603858426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638158892603858426" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638158892603858426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638158892603858426" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638158892603858426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638158892603858426" xlink:to="us-gaap_LiabilitiesCurrent_638158892603858426" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638158892603858426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158892603858426" xlink:to="us-gaap_AccountsPayableCurrent_638158892603858426" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638158892603858426" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158892603858426" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638158892603858426" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_AccruedClinicalSiteCosts" xlink:label="nrxp_AccruedClinicalSiteCosts_638158892603866782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158892603858426" xlink:to="nrxp_AccruedClinicalSiteCosts_638158892603866782" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_638158892603866782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158892603858426" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_638158892603866782" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_638158892603866782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158892603858426" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_638158892603866782" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_ConvertibleNotesPayableAccruedInterest" xlink:label="nrxp_ConvertibleNotesPayableAccruedInterest_638158892603866782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158892603858426" xlink:to="nrxp_ConvertibleNotesPayableAccruedInterest_638158892603866782" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_NotesPayableAndAccruedInterestCurrent" xlink:label="nrxp_NotesPayableAndAccruedInterestCurrent_638158892603866782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158892603858426" xlink:to="nrxp_NotesPayableAndAccruedInterestCurrent_638158892603866782" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_NotesPayableAndAccruedInterestNonCurrent" xlink:label="nrxp_NotesPayableAndAccruedInterestNonCurrent_638158892603866782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638158892603858426" xlink:to="nrxp_NotesPayableAndAccruedInterestNonCurrent_638158892603866782" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158892603866782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638158892603866782" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638158892603866782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158892603866782" xlink:to="us-gaap_PreferredStockValue_638158892603866782" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638158892603876659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158892603866782" xlink:to="us-gaap_CommonStockValue_638158892603876659" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638158892603876659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158892603866782" xlink:to="us-gaap_AdditionalPaidInCapital_638158892603876659" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638158892603876659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158892603866782" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638158892603876659" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158892603876659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_638158892603876659" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158892603876659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638158892603876659" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158892603876659" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638158892603876659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158892603876659" xlink:to="us-gaap_OperatingIncomeLoss_638158892603876659" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638158892603876659" xlink:to="us-gaap_OperatingExpenses_638158892603886780" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638158892603886780" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638158892603886780" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638158892603886780" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638158892603886780" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_SettlementExpense" xlink:label="nrxp_SettlementExpense_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638158892603886780" xlink:to="nrxp_SettlementExpense_638158892603886780" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_ExpenseReimbursement" xlink:label="nrxp_ExpenseReimbursement_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638158892603886780" xlink:to="nrxp_ExpenseReimbursement_638158892603886780" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158892603876659" xlink:to="us-gaap_NonoperatingIncomeExpense_638158892603886780" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638158892603886780" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638158892603886780" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638158892603886780" xlink:to="us-gaap_InterestIncomeOther_638158892603886780" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638158892603886780" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638158892603886780" xlink:to="us-gaap_InterestExpense_638158892603886780" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_IncreaseDecreaseInFairValueOfConvertibleDebt" xlink:label="nrxp_IncreaseDecreaseInFairValueOfConvertibleDebt_638158892603896831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638158892603886780" xlink:to="nrxp_IncreaseDecreaseInFairValueOfConvertibleDebt_638158892603896831" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638158892603896831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638158892603886780" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638158892603896831" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_GainLossOnFairValueOfCashEarnoutLiability" xlink:label="nrxp_GainLossOnFairValueOfCashEarnoutLiability_638158892603896831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638158892603886780" xlink:to="nrxp_GainLossOnFairValueOfCashEarnoutLiability_638158892603896831" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_DeemedDividendWarrants" xlink:label="nrxp_DeemedDividendWarrants_638158892603896831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="nrxp_DeemedDividendWarrants_638158892603896831" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638158892603896831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638158892603896831" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638158892603906756" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638158892603906756" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638158892603906756" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638158892603906756" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638158892603906756" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638158892603906756" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_NonCashConsultingExpense" xlink:label="nrxp_NonCashConsultingExpense_638158892603906756" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="nrxp_NonCashConsultingExpense_638158892603906756" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_NoncashSettlementExpense" xlink:label="nrxp_NoncashSettlementExpense_638158892603906756" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="nrxp_NoncashSettlementExpense_638158892603906756" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638158892603906756" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_PaidInKindInterest_638158892603906756" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_IncreaseDecreaseInFairValueOfConvertibleDebt" xlink:label="nrxp_IncreaseDecreaseInFairValueOfConvertibleDebt_638158892603906756" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="nrxp_IncreaseDecreaseInFairValueOfConvertibleDebt_638158892603906756" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_GainLossOnFairValueOfCashEarnoutLiability" xlink:label="nrxp_GainLossOnFairValueOfCashEarnoutLiability_638158892603916561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="nrxp_GainLossOnFairValueOfCashEarnoutLiability_638158892603916561" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638158892603916561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638158892603916561" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638158892603916561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638158892603916561" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638158892603926775" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_ShareBasedCompensation_638158892603926775" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638158892603926775" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_ProfitLoss_638158892603926775" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638158892603926775" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158892603896831" xlink:to="us-gaap_Depreciation_638158892603926775" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158892603926775" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158892603926775" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638158892603926775" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158892603926775" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638158892603926775" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638158892603936644" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638158892603936644" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638158892603946779" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638158892603946779" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638158892603946779" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="us-gaap_ProceedsFromWarrantExercises_638158892603946779" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638158892603946779" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638158892603946779" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_ProceedsFromIssuanceOfCommonStockAndExerciseOfStockOptions" xlink:label="nrxp_ProceedsFromIssuanceOfCommonStockAndExerciseOfStockOptions_638158892603946779" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="nrxp_ProceedsFromIssuanceOfCommonStockAndExerciseOfStockOptions_638158892603946779" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638158892603946779" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638158892603946779" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_638158892603956878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_638158892603956878" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" xlink:label="nrxp_NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_638158892603956878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="nrxp_NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_638158892603956878" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_ProceedsFromRepaymentsOfNotesPayableAssumedInMerger" xlink:label="nrxp_ProceedsFromRepaymentsOfNotesPayableAssumedInMerger_638158892603956878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="nrxp_ProceedsFromRepaymentsOfNotesPayableAssumedInMerger_638158892603956878" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_638158892603956878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158892603926775" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_638158892603956878" order="10" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/DisclosureReverseRecapitalizationEffectOnCashFlowsAndEquityDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Reverse Recapitalization - Effect on Cash Flows and Equity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_BusinessCombinationCashHeldInTrustUsedForFundingNetOfRedemption" xlink:label="nrxp_BusinessCombinationCashHeldInTrustUsedForFundingNetOfRedemption_638158892603966787" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2" xlink:to="nrxp_BusinessCombinationCashHeldInTrustUsedForFundingNetOfRedemption_638158892603966787" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_BusinessCombinationCashInflowPipeFinancingNetOfTransactionCosts" xlink:label="nrxp_BusinessCombinationCashInflowPipeFinancingNetOfTransactionCosts_638158892603966787" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2" xlink:to="nrxp_BusinessCombinationCashInflowPipeFinancingNetOfTransactionCosts_638158892603966787" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638158892603976778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638158892603976778" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts" xlink:label="nrxp_StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredNetWorkingCapitalAssumed" xlink:label="nrxp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredNetWorkingCapitalAssumed_638158892603976778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts" xlink:to="nrxp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredNetWorkingCapitalAssumed_638158892603976778" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_BusinessCombinationEffectOnEquityOfNotesPayableAssumed" xlink:label="nrxp_BusinessCombinationEffectOnEquityOfNotesPayableAssumed_638158892603976778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts" xlink:to="nrxp_BusinessCombinationEffectOnEquityOfNotesPayableAssumed_638158892603976778" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_BusinessCombinationEffectOnEquityOfPlacementWarrantsAssumed" xlink:label="nrxp_BusinessCombinationEffectOnEquityOfPlacementWarrantsAssumed_638158892603976778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts" xlink:to="nrxp_BusinessCombinationEffectOnEquityOfPlacementWarrantsAssumed_638158892603976778" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_BusinessCombinationEffectOnEquityOfEarnoutCash" xlink:label="nrxp_BusinessCombinationEffectOnEquityOfEarnoutCash_638158892603976778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts" xlink:to="nrxp_BusinessCombinationEffectOnEquityOfEarnoutCash_638158892603976778" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_NetOfRedemptionsAndIssuanceCosts" xlink:label="nrxp_NetOfRedemptionsAndIssuanceCosts_638158892603976778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nrxp_StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts" xlink:to="nrxp_NetOfRedemptionsAndIssuanceCosts_638158892603976778" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638158892603986768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:to="us-gaap_PrepaidInsurance_638158892603986768" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_PrepaidLegalExpenses" xlink:label="nrxp_PrepaidLegalExpenses_638158892603986768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:to="nrxp_PrepaidLegalExpenses_638158892603986768" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_PrepaidManufacturingExpensesCurrent" xlink:label="nrxp_PrepaidManufacturingExpensesCurrent_638158892603986768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:to="nrxp_PrepaidManufacturingExpensesCurrent_638158892603986768" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_638158892603986768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_638158892603986768" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638158892603986768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638158892603986768" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_PrepaidClinicalDevelopmentExpenses" xlink:label="nrxp_PrepaidClinicalDevelopmentExpenses_638158892603986768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:to="nrxp_PrepaidClinicalDevelopmentExpenses_638158892603986768" order="6" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638158892603986768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_2" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638158892603986768" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="nrxp_AccruedResearchAndDevelopmentExpensesCurrent_638158892603996821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_2" xlink:to="nrxp_AccruedResearchAndDevelopmentExpensesCurrent_638158892603996821" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_638158892603996821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_2" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_638158892603996821" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_OtherAccruedExpensesCurrent" xlink:label="nrxp_OtherAccruedExpensesCurrent_638158892603996821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_2" xlink:to="nrxp_OtherAccruedExpensesCurrent_638158892603996821" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/DisclosureFairValueMeasurementsConvertibleNotePayableDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fair Value Measurements - Convertible Note Payable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638158892603996821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638158892603996821" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638158892603996821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638158892603996821" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalIncomeTaxRateDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Reconciliation of the statutory U.S. federal income tax rate (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158892604006771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158892604006771" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationFairMarketValueEarnout" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationFairMarketValueEarnout_638158892604006771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationFairMarketValueEarnout_638158892604006771" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_638158892604006771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_638158892604006771" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants" xlink:label="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants_638158892604006771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="nrxp_EffectiveIncomeTaxRateReconciliationSettlementWarrants_638158892604006771" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638158892604006771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638158892604006771" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638158892604006771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638158892604006771" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158892604016559" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158892604016559" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158892604016559" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158892604016559" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638158892604016559" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638158892604016559" order="9" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Components of income tax provision (benefit) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638158892604016559" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638158892604016559" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_638158892604016559" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_638158892604016559" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638158892604016559" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638158892604016559" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_638158892604026754" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_638158892604026754" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://nrxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638158892604026754" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638158892604026754" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158892604026754" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158892604026754" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158892604026754" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_DeferredTaxAssetsCommonStockWarrants" xlink:label="nrxp_DeferredTaxAssetsCommonStockWarrants_638158892604026754" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158892604026754" xlink:to="nrxp_DeferredTaxAssetsCommonStockWarrants_638158892604026754" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638158892604026754" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158892604026754" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638158892604026754" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_DeferredTaxAssets174Capitalization" xlink:label="nrxp_DeferredTaxAssets174Capitalization_638158892604026754" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158892604026754" xlink:to="nrxp_DeferredTaxAssets174Capitalization_638158892604026754" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158892604026754" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158892604026754" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158892604026754" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638158892604026754" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158892604026754" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638158892604026754" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638158892604036787" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158892604026754" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638158892604036787" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrxp-20221231.xsd#nrxp_DeferredTaxLiabilitiesDepreciation" xlink:label="nrxp_DeferredTaxLiabilitiesDepreciation_638158892604036787" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158892604026754" xlink:to="nrxp_DeferredTaxLiabilitiesDepreciation_638158892604036787" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638158892604036787" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638158892604036787" order="2" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
